Dystrophic Epidermolysis Bullosa Treatment Market (By Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, Others; By Disease Type: DDEB and RDEB; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030

Published Date : Jul 2021 | No. of Pages : 150+ Pages | Category : Healthcare

Global dystrophic epidermolysis bullosa treatment market size is predicted to surpass around US$ 715 million by 2030 from US$ 415 Mn in 2020, expanding growth at a CAGR of 5.1% from 2021 to 2030.

Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated at 3.3 per million people.

Rise in prevalence of dystrophic epidermolysis bullosa and surge in research for managing dystrophic epidermolysis bullosa are projected to drive the global dystrophic epidermolysis bullosa treatment market during the forecast period.

Advent of New Treatment Modalities to Drive Global Market

The increasing prevalence of epidermolysis bullosa– a set of hereditary skin blistering diseases has prompted researchers and scientists to seek newer treatment modalities – a factor that is expected to drive the global dystrophic epidermolysis bullosa treatment market during the assessment period. Furthermore, as researchers have gained immense knowledge pertaining to the genetic mutation of dystrophic epidermolysis bullosa, newer treatment modalities are currently making inroads into the global dystrophic epidermolysis bullosa treatment market. The increasing understanding of disease etio-pathogenesis is a top factor that is accelerating the development of new and cutting-edge therapy alternatives. In the current scenario, cell-based and first gene therapies are increasingly being tested in clinical trials and at the preclinical level. Moreover, the increasing knowledge of various secondary disease mechanisms has paved the way for clinical testing and development of symptom-relief therapies, including dystrophic epidermolysis bullosa treatment– a major factor that is anticipated to fuel the growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period.

Research and Development Activities in Full Swing amid COVID-19 Pandemic

The COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period. Research and development activities for dystrophic epidermolysis bullosa treatment are underway to identify the potential threat of the novel SARS-CoV-2 virus to patients suffering from dystrophic epidermolysis bullosa. Several studies have revealed that patients suffering from epidermolysis bullosa, particularly with syndromic forms are at a higher risk of acquiring the novel COVID-19 infection.

Overall, the outbreak of the COVID-19 pandemic is expected to accelerate research and development activities, thereby opening new avenues.

Strides Taken by Gene Therapy and Tissue Engineering to Fuel Adoption

Due to the notable progress made by gene therapy and tissue engineering, dystrophic epidermolysis bullosa treatment has improved by a considerable margin. Moreover, apart from these alternatives, stem cell transplantation and gene correction are some of the other treatment alternatives that are likely to gain adoption in the global dystrophic epidermolysis bullosa treatment market during the assessment period. A number of research and development activities has indicated that in vitro gene therapy of keratinocyte stem cells and transplanting the same into the skin is one of the most promising and novel treatments that is likely to gain considerable adoption in the upcoming years. Scientists and stakeholders operating in the current dystrophic epidermolysis bullosa treatment market landscape are also focusing on enhancing the clinical features in epidermolysis bullosa patients by relying on in vitro gene therapy of stem cell keratinocytes– a factor that is projected to boost the global dystrophic epidermolysis bullosa treatment market during the assessment period.

Report Highlights

In terms of treatment type, the global dystrophic epidermolysis bullosa treatment market has been classified into antibiotics, corticosteroids, opioid analgesics, anticonvulsant, and others. The antibiotics segment dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is projected to continue during the forecast period. A large number of antibiotics is in late phases of clinical pipeline trials and are likely to be commercialized between 2019 and 2025. Anticipated launch and adoption of antibiotics to address unmet medical needs in dystrophic epidermolysis bullosa treatment are expected to propel the segment during the forecast period.

Based on service provider, the global dystrophic epidermolysis bullosa treatment market has been bifurcated into dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). The dominant dystrophic epidermolysis bullosa (DDEB) segment dominated the global dystrophic epidermolysis bullosa treatment market due to large number of patients suffering from dominant dystrophic epidermolysis bullosa. According to the National EB Registry, the overall prevalence of EB is 11.07 per one million live births. The prevalence of DDEB and RDEB is 1.49 and 1.35 per one million live births, respectively.

North America dominated the global dystrophic epidermolysis bullosa treatment market in 2020 and the trend is anticipated to continue during the forecast period. The rise in population suffering from various diseases in North America has increased the number of patients visiting hospitals. Hence, the consumption of dystrophic epidermolysis bullosa treatment products is expected to increase during the forecast period. North America’s large share of the global dystrophic epidermolysis bullosa treatment market can be attributed to high cost of biologic drugs compared to other regions. It is a key target region for all players in the global dystrophic epidermolysis bullosa treatment market. 

Asia Pacific is likely to be a highly lucrative market for dystrophic epidermolysis bullosa treatment from 2021 to 2030. The market in the region is projected to expand at a high CAGR during the forecast period.

Key Players

Key players in the global dystrophic epidermolysis bullosa treatment market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate S.r.l.

Market Segmentation

By Treatment Type

    • Antibiotics
    • Corticosteroids
    • Opioid Analgesics
    • Anticonvulsant
    • Others

By Disease Type

    • Dominant Dystrophic Epidermolysis Bullosa (DDEB)
    • Recessive Dystrophic Epidermolysis Bullosa (RDEB)

By Distribution Channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

 

This report focuses on dystrophic epidermolysis bullosa treatment market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall dystrophic epidermolysis bullosa treatment market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global dystrophic epidermolysis bullosa treatment market.

The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.

In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).

The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.

The report provides in-depth segment analysis of the global dystrophic epidermolysis bullosa treatment market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the dystrophic epidermolysis bullosa treatment market.

The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.

In this study, the years considered to estimate the market size of dystrophic epidermolysis bullosa treatment are as follows:

  • History Year: 2017-2019
  • Base Year: 2020
  • Forecast Year 2021 to 2030

Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.

The analysts have provided a comprehensive analysis of the competitive landscape of the global dystrophic epidermolysis bullosa treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers

 Research Methodology

The research methodology adopted by analysts for compiling the global dystrophic epidermolysis bullosa treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global dystrophic epidermolysis bullosa treatment market.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2021) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

 


Featured Research Reports

  • Featured Research Reports

    Clinical Trial Equipment & Ancillary Solutions Market (By Product: Sourcing, Supply/Logistics, Service, Others; By Phase: Phase I, Phase II, Phase III, Phase IV) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Dental Suction Systems Market (By Product: Wet Suction, Dry Suction; By End-use: Hospitals, Dental Offices) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Dental Caries Detectors Market (By Product: Laser Fluorescent Caries Detector, Fiber Optic Trans-illumination Caries Detector; By End-use: Hospitals, Dental Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Ophthalmic Perimeters Market (By Product: Static, Kinetic, Combination; By End-use: Hospital, Ophthalmic Clinic, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Investigational New Drug CDMO Market (By Product: Small Molecule, Large Molecule; By Service: Contract Development, Contract Manufacturing; By End-use: Pharmaceutical Companies, Biotech Companies, Others (Government, Research Institutes, Academic Institutes, etc.)) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...